piperacillin/tazobactam

pi-PER-a-sill-in/tay-zoe-BAK-tam

Therapeutic Classification: anti-infectives

Pharmacologic Classification: extended spectrum penicillins

REMS

Appendicitis and peritonitis.
Skin and skin structure infections.
Gynecologic infections.
Community-acquired and nosocomial pneumonia.

Piperacillin

Binds to bacterial cell wall membrane, causing cell death. Spectrum is extended compared with other penicillins.

Tazobactam

Inhibits beta-lactamase, an enzyme that can destroy penicillins.

Therapeutic effects:

Death of susceptible bacteria.

Spectrum:

Active against piperacillin-resistant beta-lactamase producing:
- Bacteroides fragilis,
- E. coli,
- Acinetobacter baumanii,
- Klebsiella pneumoniae,
- Pseudomonas aeruginosa,
- Staphylococcus aureus,
- Haemophilus influenzae.

Absorption: IV administration results in complete bioavailability.

Distribution: Widely distributed. Enters CSF well only when meninges are inflamed.

Metabolism/Excretion: Piperacillin (68%) and tazobactam (80%) are mostly excreted unchanged by the kidneys.

Half-Life: Adults: 0.7–1.2 hr; Children (6 mo–12 yr): 0.7–0.9 hr; Infants (2–5 mo): 1.4 hr.

(piperacillin plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
IV	rapid	end of infusion	4–6 hr

Contraindicated in:

Hypersensitivity to penicillins, beta-lactams, cephalosporins, or tazobactam (cross-sensitivity may occur).

Use Cautiously in:

Renal impairment (↑ risk of seizures) (↓ dose or ↑ interval recommended if CCr <40 mL/min);
Seizure disorders;
Sodium restriction;
Critically ill patients (↑ risk of renal failure; use alternative antibiotic, if possible);
OB: Safety not established in pregnancy;
Lactation: Safety not established in breastfeeding;
Pedi: Children <2 mo (safety and effectiveness not established).

Derm: rash (↑ in patients with cystic fibrosis), ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN), urticaria

GI: diarrhea, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), constipation, drug-induced hepatitis, nausea, vomiting

GU: interstitial nephritis, renal failure

Hemat: bleeding, leukopenia, neutropenia, thrombocytopenia

Local: pain, phlebitis

MS: RHABDOMYOLYSIS

Neuro: confusion, dizziness, headache, insomnia, lethargy, SEIZURES (HIGHER DOSES)

Misc: fever(↑ in patients with cystic fibrosis), hemophagocytic lymphohistiocytosis, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND SERUM SICKNESS), superinfection

Drug-drug:

Probenecid↓ renal excretion and ↑ levels.
May alter excretion of lithium.
Potassium-losing diuretics, corticosteroids, or amphotericin B may ↑ risk of hypokalemia.
↑risk of hepatotoxicity with other hepatotoxic agents.
May ↓ levels/effects of aminoglycosides in patients with renal impairment.
May ↑ levels and risk of toxicity of methotrexate.
Vancomycin may ↑ risk of acute kidney injury.
May prolong the neuromuscular blockade associated with vecuronium.

Contains 2.84 mEq (65 mg) sodium/g of piperacillin; adult doses below expressed as combined piperacillin/tazobactam content.

Appendicitis/Peritonitis

IV (Adults and Children ≥2 mo and >40 kg): 3.375 g every 6 hr.
IV (Children ≥9 mo and ≤40 kg): 112.5 mg/kg every 8 hr.
IV (Infants 2–9 mo and ≤40 kg): 90 mg/kg every 8 hr.

Renal Impairment

IV (Adults ): CCr 20–40 mL/min: 2.25 g every 6 hr; CCr <20 mL/min: 2.25 g every 8 hr; Hemodialysis: 2.25 g every 12 hr + 0.75 g following hemodialysis on hemodialysis days; Continuous ambulatory peritoneal dialysis: 2.25 g every 12 hr.

Nosocomial Pneumonia

IV (Adults and Children ≥2 mo and >40 kg): 4.5 g every 6 hr.
IV (Children ≥9 mo and ≤40 kg): 112.5 mg/kg every 6 hr.
IV (Infants 2–9 mo and ≤40 kg): 90 mg/kg every 6 hr.

Renal Impairment

IV (Adults ): CCr 20–40 mL/min: 3.375 g every 6 hr; CCr <20 mL/min: 2.25 g every 6 hr; Hemodialysis: 2.25 g every 8 hr + 0.75 g following hemodialysis on hemodialysis days; Continuous ambulatory peritoneal dialysis: 2.25 g every 8 hr.

Skin and Skin Structure Infections, Gynecologic Infections, and Community-Acquired Pneumonia

IV (Adults ): 3.375 g every 6 hr.

Renal Impairment

IV (Adults ): CCr 20–40 mL/min: 2.25 g every 6 hr; CCr <20 mL/min: 2.25 g every 8 hr; Hemodialysis: 2.25 g every 12 hr + 0.75 g following hemodialysis on hemodialysis days; Continuous ambulatory peritoneal dialysis: 2.25 g every 12 hr.

(Generic available)

Powder for injection: 2.25 g (2 g piperacillin/0.25 g tazobactam)/vial; 3.375 g (3 g piperacillin/0.375 g tazobactam)/vial; 4.5 g (4 g piperacillin/0.5 g tazobactam)/vial; 13.5 g (12 g piperacillin/1.5 g tazobactam)/vial; 40.5 g (36 g piperacillin/4.5 g tazobactam)/vial
Premixed infusion: 2.25 g (2 g piperacillin/0.25 g tazobactam) in 50 mL of 0.45% NaCl; 3.375 g (3 g piperacillin/0.375 g tazobactam) in 50 mL of 0.3% NaCl; 4.5 g (4 g piperacillin/0.5 g tazobactam) in 100 mL of 0.45% NaCl

Assess for resolving infection (WBC and vital signs trends; appearance of wound, sputum, urine, and stool) at beginning of and during therapy.
Obtain a history before initiating therapy to determine previous use of and reactions to other beta-lactam antibiotics including cephalosporins. Persons with a negative history may still have an allergic response.
Observe for signs/symptoms of anaphylaxis (rash, pruritus, laryngeal edema, wheezing). If anaphylaxis occurs, discontinue piperacillin/tazobactam. Keep epinephrine, an antihistamine, and resuscitation equipment close by in the event of an anaphylactic reaction.
Monitor for signs/symptoms of CDAD, including watery diarrhea with mucus, fever, abdominal pain or cramping, anorexia, nausea, and, in severe cases, dehydration and blood or pus in the stool. May begin up to several weeks after therapy. Report promptly to health care provider.
Assess for rash or signs and symptoms of skin reactions, including TEN or SJS, frequently during therapy (fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis, and/or eosinophilia). Discontinue at 1st sign of rash and provide supportive care; may be life-threatening. May recur once treatment is stopped.
Monitor for signs and symptoms of DRESS (fever, rash, lymphadenopathy, and/or facial swelling), associated with involvement of other organ systems (hepatitis, nephritis, hematologic abnormalities, myocarditis, myositis) during therapy. May resemble an acute viral infection. Eosinophilia is often present. If signs/symptoms of DRESS occur, discontinue piperacillin/tazobactam.
Monitor for signs and symptoms of rhabdomyolysis (malaise, myalgia, muscle cramps or weakness, dark or tea-colored urine).
Monitor for seizure activity, particularly in patients with renal impairment; discontinue therapy if seizure occurs and treat as clinically indicated. Institute seizure precautions.
Assess for signs and symptoms of superinfection such as oral thrush (white or yellow patches) or genital mycotic infections (pruritus and yeasty discharge). Treat infection promptly.
Monitor for signs and symptoms of hemophagocytic lymphohistiocytosis (fever, rash, lymphadenopathy, hepatosplenomegaly, cytopenia); if these occur , discontinue piperacillin/tazobactam immediately and treat as needed.

Lab Test Considerations:

Evaluate renal and hepatic function, CBC with differential, and electrolytes prior to and routinely during therapy.
- Obtain specimens for culture and sensitivity prior to initiating therapy. 1st dose may be given before receiving results.
- May cause positive direct Coombs test.
- Monitor renal and hepatic function before starting and routinely during therapy. May ↑ BUN, serum creatinine, AST, ALT, serum bilirubin, alkaline phosphatase, and LDH.
- Monitor CBC with differential before starting and routinely during therapy. May cause leukopenia and neutropenia, especially with prolonged therapy or in hepatic impairment. May also cause ↓ hemoglobin and hematocrit, thrombocytopenia, and eosinophilia.
- May ↑ prothrombin and partial thromboplastin time.

IV Administration:

If a dose of piperacillin/tazobactam is required that does not equal 2.25 g, 3.375 g, or 4.5 g, premixed infusion should not be used.
Intermittent Infusion: Reconstitution: Reconstitute 2.25 g, 3.375 g, and 4.5 g single-dose vials with 10 mL, 15 mL, and 20 mL, respectively of 0.9% NaCl, sterile water for injection, or D5W. Swirl until dissolved. Concentration: 202.5 mg/mL (180 mg/mL of piperacillin and 22.5 mg/mL of tazobactam).Diluent: Dilute further in 50–150 mL of 0.9% NaCl, D5W, D5/0.9% NaCl, or LR. Concentration: 22.5–90 mg/mL of piperacillin/tazobactam (in children) Reconstituted vials stable for 24 hr at room temperature or 48 hr if refrigerated. Infusion stable for 24 hr at room temperature or 48 hr if refrigerated. Premixed bags are stable for 24 hr at room temperature or 14 days if refrigerated.
Rate: Infuse over 30 min.
Y-Site Compatibility:
- acetaminophen
- allopurinol
- amikacin
- aminocaproic acid
- aminophylline
- amphotericin B liposomal
- anidulafungin
- argatroban
- arsenic trioxide
- aztreonam
- bivalirudin
- bleomycin
- bumetanide
- buprenorphine
- busulfan
- butorphanol
- caffeine citrate
- calcium chloride
- calcium gluconate
- cangrelor
- carboplatin
- carmustine
- cefepime
- ceftolozane/tazobactam
- chloramphenicol
- clindamycin
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- daptomycin
- dexamethasone
- dexmedetomidine
- dexrazoxane
- diazepam
- digoxin
- dimenhydrinate
- diphenhydramine
- docetaxel
- dopamine
- enalaprilat
- ephedrine
- epinephrine
- eptifibatide
- eravacycline
- erythromycin
- esmolol
- etoposide
- etoposide phosphate
- fentanyl
- floxuridine
- fluconazole
- fludarabine
- fluorouracil
- foscarnet
- fosphenytoin
- furosemide
- granisetron
- heparin
- hetastarch
- hydrocortisone
- hydromorphone
- ifosfamide
- isoproterenol
- ketamine
- ketorolac
- leucovorin
- lidocaine
- linezolid
- lorazepam
- magnesium sulfate
- mannitol
- melphalan
- meperidine
- meropenem
- meropenem/vaborbactam
- mesna
- methotrexate
- methylprednisolone
- metoclopramide
- metoprolol
- metronidazole
- milrinone
- morphine
- naloxone
- nitroglycerin
- nitroprusside
- norepinephrine
- octreotide
- ondansetron
- oxytocin
- paclitaxel
- palonosetron
- pamidronate
- pemetrexed
- pentobarbital
- phenobarbital
- phentolamine
- phenylephrine
- plazomicin
- potassium acetate
- potassium chloride
- potassium phosphates
- procainamide
- remifentanil
- rituximab
- sargramostim
- sildenafil
- sodium acetate
- sodium bicarbonate
- sodium phosphates
- succinylcholine
- sufentanil
- sulbactam/durlobactam
- tacrolimus
- tedizolid
- telavancin
- theophylline
- thiotepa
- tigecycline
- tirofiban
- trimethoprim/sulfamethoxazole
- vasopressin
- vinblastine
- vincristine
- voriconazole
- zidovudine
- zoledronic acid
Y-Site Incompatibility:
- acyclovir
- alemtuzumab
- amiodarone
- amphotericin B deoxycholate
- caspofungin
- chlorpromazine
- ciprofloxacin
- cisplatin
- dacarbazine
- dantrolene
- daunorubicin
- diltiazem
- dobutamine
- doxorubicin hydrochloride
- doxorubicin liposomal
- doxycycline
- droperidol
- epirubicin
- famotidine
- ganciclovir
- gemcitabine
- gemtuzumab ozogamicin
- glycopyrrolate
- haloperidol
- hydralazine
- idarubicin
- insulin regular
- irinotecan
- labetalol
- levofloxacin
- methadone
- midazolam
- minocycline
- mitomycin
- mitoxantrone
- mycophenolate
- nalbuphine
- nicardipine
- pentamidine
- phenytoin
- prochlorperazine
- promethazine
- propranolol
- rocuronium
- tobramycin
- topotecan
- tranexamic acid
- trastuzumab
- vecuronium
- verapamil
- vinorelbine

Explain the purpose and side effects of piperacillin/tazobactam. Advise patient to read Patient Information before starting therapy.
Instruct patient to notify health care provider if symptoms do not improve.
Advise patients and family to call 911 and seek urgent treatment for signs and symptoms of hypersensitivity reactions (difficulty breathing; chest tightness; hives; rash; feeling light-headed; itching; swelling of the face, lips, tongue, or throat).
Advise patient to report signs of superinfection (furry overgrowth on the tongue, white patches in mouth, vaginal itching or discharge, loose or foul-smelling stools).
Caution patient to notify health care provider if fever and diarrhea occur, especially if stool contains blood, pus, or mucus. Advise patient not to treat diarrhea without consulting health care provider. May occur up to several weeks after discontinuation of medication.
Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care provider before taking other medications.
Rep: Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected or if breastfeeding.

Bactericidal action against susceptible bacteria.
Resolution of the signs and symptoms of infection. Length of time for complete resolution depends on the organism and site of infection.

Zosyn

NDC Code

0409- Hospira, Inc
- 0409-2999- Piperacillin and Tazobactam
  - 0409-2999-14- 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (0409-2999-14) / 60 mL in 1 VIAL, PHARMACY BULK PACKAGE

0409- Hospira, Inc
- 0409-3383- Piperacillin and Tazobactam
  - 0409-3383-10- 10 VIAL, SINGLE-USE in 1 CARTON (0409-3383-10) / 10 mL in 1 VIAL, SINGLE-USE (0409-3383-11)

0409- Hospira, Inc
- 0409-3385- Piperacillin and Tazobactam
  - 0409-3385-15- 10 VIAL, SINGLE-USE in 1 CARTON (0409-3385-15) / 15 mL in 1 VIAL, SINGLE-USE (0409-3385-11)

0409- Hospira, Inc
- 0409-3390- Piperacillin and Tazobactam
  - 0409-3390-10- 10 VIAL, SINGLE-USE in 1 CARTON (0409-3390-10) / 20 mL in 1 VIAL, SINGLE-USE (0409-3390-11)

0781- Sandoz Inc
- 0781-3110- Piperacillin and Tazobactam
  - 0781-3110-95- 10 VIAL, SINGLE-USE in 1 CARTON (0781-3110-95) / 10 mL in 1 VIAL, SINGLE-USE (0781-3110-90)

0781- Sandoz Inc
- 0781-3113- Piperacillin and Tazobactam
  - 0781-3113-95- 10 VIAL, SINGLE-USE in 1 CARTON (0781-3113-95) / 15 mL in 1 VIAL, SINGLE-USE (0781-3113-90)

0781- Sandoz Inc
- 0781-3114- Piperacillin and Tazobactam
  - 0781-3114-95- 10 VIAL, SINGLE-USE in 1 CARTON (0781-3114-95) / 20 mL in 1 VIAL, SINGLE-USE (0781-3114-91)

0781- Sandoz Inc
- 0781-3180- Piperacillin and Tazobactam
  - 0781-3180-94- 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (0781-3180-94) / 250 mL in 1 VIAL, PHARMACY BULK PACKAGE

0781- Sandoz Inc
- 0781-9210- Piperacillin and Tazobactam
  - 0781-9210-95- 10 VIAL, SINGLE-USE in 1 CARTON (0781-9210-95) / 10 mL in 1 VIAL, SINGLE-USE (0781-9210-90)

0781- Sandoz Inc
- 0781-9213- Piperacillin and Tazobactam
  - 0781-9213-95- 10 VIAL, SINGLE-USE in 1 CARTON (0781-9213-95) / 15 mL in 1 VIAL, SINGLE-USE (0781-9213-90)

0781- Sandoz Inc
- 0781-9214- Piperacillin and Tazobactam
  - 0781-9214-95- 10 VIAL, SINGLE-USE in 1 CARTON (0781-9214-95) / 20 mL in 1 VIAL, SINGLE-USE (0781-9214-91)

35369- Shandong Anxin Pharmaceutical Co., Ltd.
- 35369-0501- Piperacillin and Tazobactam
  - 35369-0501-2- 10 VIAL, SINGLE-DOSE in 1 CARTON (35369-0501-2) / 20 mL in 1 VIAL, SINGLE-DOSE (35369-0501-1)

35369- Shandong Anxin Pharmaceutical Co., Ltd.
- 35369-0502- Piperacillin and Tazobactam
  - 35369-0502-2- 10 VIAL, SINGLE-DOSE in 1 CARTON (35369-0502-2) / 10 mL in 1 VIAL, SINGLE-DOSE (35369-0502-1)

35369- Shandong Anxin Pharmaceutical Co., Ltd.
- 35369-0503- Piperacillin and Tazobactam
  - 35369-0503-2- 10 VIAL, SINGLE-DOSE in 1 CARTON (35369-0503-2) / 15 mL in 1 VIAL, SINGLE-DOSE (35369-0503-1)

35369- Shandong Anxin Pharmaceutical Co., Ltd.
- 35369-0504- Piperacillin and Tazobactam
  - 35369-0504-1- 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (35369-0504-1) / 180 mL in 1 VIAL, PHARMACY BULK PACKAGE

44567- WG Critical Care, LLC
- 44567-804- Piperacillin and Tazobactam
  - 44567-804-01- 1 BOTTLE in 1 BOX (44567-804-01) / 1 INJECTION, POWDER, FOR SOLUTION in 1 BOTTLE

52946- ACS Dobfar SpA
- 52946-0927-
  - 52946-0927-0- 20 kg in 1 BOX (52946-0927-0)

60505- Apotex Corp.
- 60505-6156- Piperacillin and Tazobactam
  - 60505-6156-4- 10 VIAL, SINGLE-DOSE in 1 CARTON (60505-6156-4) / 10 mL in 1 VIAL, SINGLE-DOSE (60505-6156-0)

60505- Apotex Corp.
- 60505-6157- Piperacillin and Tazobactam
  - 60505-6157-4- 10 VIAL, SINGLE-DOSE in 1 CARTON (60505-6157-4) / 15 mL in 1 VIAL, SINGLE-DOSE (60505-6157-0)

60505- Apotex Corp.
- 60505-6159- Piperacillin and Tazobactam
  - 60505-6159-4- 10 VIAL, SINGLE-DOSE in 1 CARTON (60505-6159-4) / 20 mL in 1 VIAL, SINGLE-DOSE (60505-6159-0)

60505- Apotex Corp.
- 60505-6262- Piperacillin and Tazobactam
  - 60505-6262-0- 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (60505-6262-0) / 180 mL in 1 VIAL, PHARMACY BULK PACKAGE

63323- Fresenius Kabi USA, LLC
- 63323-981- Piperacillin and Tazobactam
  - 63323-981-21- 10 VIAL, SINGLE-USE in 1 CARTON (63323-981-21) / 10 mL in 1 VIAL, SINGLE-USE (63323-981-23)

63323- Fresenius Kabi USA, LLC
- 63323-981- Piperacillin and Tazobactam
  - 63323-981-53- 10 VIAL, SINGLE-USE in 1 CARTON (63323-981-53) / 10 mL in 1 VIAL, SINGLE-USE (63323-981-41)

63323- Fresenius Kabi USA, LLC
- 63323-982- Piperacillin and Tazobactam
  - 63323-982-52- 10 VIAL, SINGLE-USE in 1 CARTON (63323-982-52) / 20 mL in 1 VIAL, SINGLE-USE (63323-982-21)

63323- Fresenius Kabi USA, LLC
- 63323-982- Piperacillin and Tazobactam
  - 63323-982-54- 10 VIAL, SINGLE-USE in 1 CARTON (63323-982-54) / 20 mL in 1 VIAL, SINGLE-USE (63323-982-43)

63323- Fresenius Kabi USA, LLC
- 63323-983- Piperacillin and Tazobactam
  - 63323-983-21- 10 VIAL, SINGLE-USE in 1 CARTON (63323-983-21) / 15 mL in 1 VIAL, SINGLE-USE (63323-983-23)

63323- Fresenius Kabi USA, LLC
- 63323-983- Piperacillin and Tazobactam
  - 63323-983-53- 10 VIAL, SINGLE-USE in 1 CARTON (63323-983-53) / 15 mL in 1 VIAL, SINGLE-USE (63323-983-41)

65219- Fresenius Kabi USA, LLC
- 65219-256- Piperacillin and Tazobactam
  - 65219-256-00- 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (65219-256-00) / 180 mL in 1 VIAL, PHARMACY BULK PACKAGE

65219- Fresenius Kabi USA, LLC
- 65219-256- Piperacillin and Tazobactam
  - 65219-256-24- 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (65219-256-24) / 180 mL in 1 VIAL, PHARMACY BULK PACKAGE

65219- Fresenius Kabi USA, LLC
- 65219-256- Piperacillin and Tazobactam
  - 65219-256-28- 1 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (65219-256-28) / 180 mL in 1 VIAL, PHARMACY BULK PACKAGE

65219- Fresenius Kabi USA, LLC
- 65219-259- Piperacillin and Tazobactam
  - 65219-259-45- 10 VIAL, SINGLE-USE in 1 CARTON (65219-259-45) / 20 mL in 1 VIAL, SINGLE-USE (65219-259-05)

65219- Fresenius Kabi USA, LLC
- 65219-259- Piperacillin and Tazobactam
  - 65219-259-55- 10 VIAL, SINGLE-USE in 1 CARTON (65219-259-55) / 20 mL in 1 VIAL, SINGLE-USE (65219-259-15)

65219- Fresenius Kabi USA, LLC
- 65219-434- Piperacillin and Tazobactam
  - 65219-434-20- 10 VIAL, SINGLE-DOSE in 1 CARTON (65219-434-20) / 10 mL in 1 VIAL, SINGLE-DOSE (65219-434-02)

65219- Fresenius Kabi USA, LLC
- 65219-436- Piperacillin and Tazobactam
  - 65219-436-20- 10 VIAL, SINGLE-DOSE in 1 CARTON (65219-436-20) / 15 mL in 1 VIAL, SINGLE-DOSE (65219-436-02)

68001- BluePoint Laboratories
- 68001-506- Piperacillin and Tazobactam
  - 68001-506-30- 10 VIAL, SINGLE-DOSE in 1 CARTON (68001-506-30) / 10 mL in 1 VIAL, SINGLE-DOSE (68001-506-28)

68001- BluePoint Laboratories
- 68001-507- Piperacillin and Tazobactam
  - 68001-507-82- 10 VIAL, SINGLE-DOSE in 1 CARTON (68001-507-82) / 15 mL in 1 VIAL, SINGLE-DOSE (68001-507-53)

68001- BluePoint Laboratories
- 68001-508- Piperacillin and Tazobactam
  - 68001-508-31- 10 VIAL, SINGLE-DOSE in 1 CARTON (68001-508-31) / 20 mL in 1 VIAL, SINGLE-DOSE (68001-508-29)

72485- Armas Pharmaceuticals Inc.
- 72485-403- piperacillin and tazobactam
  - 72485-403-10- 10 VIAL, SINGLE-DOSE in 1 BOX (72485-403-10) / 15 mL in 1 VIAL, SINGLE-DOSE (72485-403-01)

72485- Armas Pharmaceuticals Inc.
- 72485-404- piperacillin and tazobactam
  - 72485-404-10- 10 VIAL, SINGLE-DOSE in 1 BOX (72485-404-10) / 20 mL in 1 VIAL, SINGLE-DOSE (72485-404-01)

72572- Civica, Inc.
- 72572-414- piperacillin and tazobactam
  - 72572-414-10- 10 VIAL, SINGLE-USE in 1 CARTON (72572-414-10) / 15 mL in 1 VIAL, SINGLE-USE

72572- Civica, Inc.
- 72572-418- piperacillin and tazobactam
  - 72572-418-10- 10 VIAL, SINGLE-USE in 1 CARTON (72572-418-10) / 20 mL in 1 VIAL, SINGLE-USE

83270- ONESOURCE SPECIALTY PHARMA LIMITED
- 83270-301- piperacillin and tazobactam
  - 83270-301-10- 10 VIAL, SINGLE-USE in 1 CARTON (83270-301-10) / 10 mL in 1 VIAL, SINGLE-USE

83270- ONESOURCE SPECIALTY PHARMA LIMITED
- 83270-302- piperacillin and tazobactam
  - 83270-302-10- 10 VIAL, SINGLE-USE in 1 CARTON (83270-302-10) / 15 mL in 1 VIAL, SINGLE-USE

83270- ONESOURCE SPECIALTY PHARMA LIMITED
- 83270-303- piperacillin and tazobactam
  - 83270-303-10- 10 VIAL, SINGLE-USE in 1 CARTON (83270-303-10) / 20 mL in 1 VIAL, SINGLE-USE

83634- Avenacy, LLC
- 83634-104- Piperacillin and Tazobactam
  - 83634-104-20- 10 VIAL, SINGLE-DOSE in 1 CARTON (83634-104-20) / 10 mL in 1 VIAL, SINGLE-DOSE (83634-104-41)

83634- Avenacy, LLC
- 83634-105- Piperacillin and Tazobactam
  - 83634-105-30- 10 VIAL, SINGLE-DOSE in 1 CARTON (83634-105-30) / 15 mL in 1 VIAL, SINGLE-DOSE (83634-105-41)

83634- Avenacy, LLC
- 83634-106- Piperacillin and Tazobactam
  - 83634-106-50- 10 VIAL, SINGLE-DOSE in 1 CARTON (83634-106-50) / 20 mL in 1 VIAL, SINGLE-DOSE (83634-106-41)

83634- Avenacy, LLC
- 83634-112- Piperacillin and Tazobactam
  - 83634-112-99- 1 BOTTLE in 1 CARTON (83634-112-99) / 180 mL in 1 BOTTLE

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Code ⬆